SciELO - Scientific Electronic Library Online

 
vol.44 número2Consenso para identificar los riesgos de los medicamentos peligrosos en los servicios de farmacia hospitalariaTerapias modificadoras de la enfermedad en esclerosis múltiple: revisión sistemática de costo-efectividad índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Farmacia Hospitalaria

versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343

Resumen

CALVO-ARBELOA, María; INSAUSTL-SERRANO, Ana María; ARRONDO-VELASCO, Amaya  y  SAROBE-CARRICAS, María Teresa. Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease. Farm Hosp. [online]. 2020, vol.44, n.2, pp.62-67.  Epub 28-Sep-2020. ISSN 2171-8695.  http://dx.doi.org/10.7399/fh.11325.

Objective:

Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab and ustekinumab are three biologic agents that patients can self-administer subcutaneously after collecting them from the pharmacy department. However, for the treatment to be effective, adherence is paramount. The purpose of the present study is to evaluate adherence in patients who collected all three drugs from the dispensary of a tertiary care hospital.

Method:

A cross-sectional observational analysis was carried out of patients who had been receiving treatment with adalimumab, golimumab and ustekinumab for at least four months. The medication possession ratio was calculated based on information extracted from the pharmacy dispensing records. Patients with a ratio < 85% were enrolled in the study and asked to respond to Morisky-Green Medication Adherence Questionnaire.

Results:

One-hundred and seventy-eight patients were included, of whom 60.1% (107) were male and 30.9% (55) had been treated pre viously with other biologics. According to the pharmacy dispensing re cords, mean adherence was 91.79%, with 45 patients (25.28%) classified as scarcely compliant (< 85%). The Morisky-Green Medication Adherence Questionnaire revealed that carelessness about administering the drug at the right time and forgetfulness were the main reasons for therapeutic non-adherence. Female sex (odds ratio 0.42; p = 0.013) and lengthy treatments (p = 0.002) were associated to lower adherence rates.

Conclusions:

Although most patients in the studied population were seen to be compliant, low levels of adherence were observed in a number of patients who would benefit from interventions aimed at boosting their adherence. It must be said, however, that the statistical power of this study should be enhanced in order to increase the significance of the results obtained.

Palabras clave : Therapeutic adherence; Biological therapy; Adalimumab; Golimumab; Ustekinumab; Inflammatory bowel disease.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )